Local and National Advocacy Support
Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to d...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical immunology 2012-09, Vol.32 (Suppl 2), p.423-426 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 426 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | 423 |
| container_title | Journal of clinical immunology |
| container_volume | 32 |
| creator | Shapiro, Ralph S. Boyle, Marcia Perez, Elena E. |
| description | Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient’s experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies. |
| doi_str_mv | 10.1007/s10875-012-9736-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3459078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1082235023</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-6c704e777c33eb3ea61e68e04af4d02835c8f1a7bd518c4606ef086e07c6d5d83</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBcpePESnXzvXgQpfkHRg3oOaTZbt2w3Ndkt9N-bsrXoxdMw877zzvAgdE7gmgCom0ggUwIDoThXTGJ5gIZEKIapyOkhGgJVBOeE0wE6iXEBAExScYwGlGYEJFVDdDn11tRj0xTjF9NWvknNXbFOQ7sZv3WrlQ_tKToqTR3d2a6O0MfD_fvkCU9fH58nd1NsOactllYBd0opy5ibMWckcTJzwE3JC6AZEzYriVGzQpDMcgnSlZBJB8rKQhQZG6HbPnfVzZausK5pg6n1KlRLEzbam0r_VZrqU8_9WjMuclDbgKtdQPBfnYutXlbRuro2jfNd1AkXpUwAZclKeqsNPsbgyv0ZAnoLV_dwdYKrt3C1TDsXv__bb_zQTAbaG2KSmrkLeuG7kJDGf1K_AZjFhBI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1082235023</pqid></control><display><type>article</type><title>Local and National Advocacy Support</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Shapiro, Ralph S. ; Boyle, Marcia ; Perez, Elena E.</creator><creatorcontrib>Shapiro, Ralph S. ; Boyle, Marcia ; Perez, Elena E.</creatorcontrib><description>Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient’s experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-012-9736-6</identifier><identifier>PMID: 22810627</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Decision Making, Organizational ; Health Services Accessibility ; Humans ; Immunoglobulins, Intravenous - economics ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Deficiency Syndromes - drug therapy ; Immunologic Deficiency Syndromes - economics ; Immunology ; Infectious Diseases ; Internal Medicine ; Medical Microbiology ; Patient Advocacy - economics ; Patient Advocacy - legislation & jurisprudence ; Patient Preference - economics ; Patient Preference - legislation & jurisprudence ; Precision Medicine</subject><ispartof>Journal of clinical immunology, 2012-09, Vol.32 (Suppl 2), p.423-426</ispartof><rights>The Author(s) 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-6c704e777c33eb3ea61e68e04af4d02835c8f1a7bd518c4606ef086e07c6d5d83</citedby><cites>FETCH-LOGICAL-c442t-6c704e777c33eb3ea61e68e04af4d02835c8f1a7bd518c4606ef086e07c6d5d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-012-9736-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-012-9736-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22810627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shapiro, Ralph S.</creatorcontrib><creatorcontrib>Boyle, Marcia</creatorcontrib><creatorcontrib>Perez, Elena E.</creatorcontrib><title>Local and National Advocacy Support</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><addtitle>J Clin Immunol</addtitle><description>Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient’s experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Decision Making, Organizational</subject><subject>Health Services Accessibility</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - economics</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Deficiency Syndromes - drug therapy</subject><subject>Immunologic Deficiency Syndromes - economics</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medical Microbiology</subject><subject>Patient Advocacy - economics</subject><subject>Patient Advocacy - legislation & jurisprudence</subject><subject>Patient Preference - economics</subject><subject>Patient Preference - legislation & jurisprudence</subject><subject>Precision Medicine</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlZ_gBcpePESnXzvXgQpfkHRg3oOaTZbt2w3Ndkt9N-bsrXoxdMw877zzvAgdE7gmgCom0ggUwIDoThXTGJ5gIZEKIapyOkhGgJVBOeE0wE6iXEBAExScYwGlGYEJFVDdDn11tRj0xTjF9NWvknNXbFOQ7sZv3WrlQ_tKToqTR3d2a6O0MfD_fvkCU9fH58nd1NsOactllYBd0opy5ibMWckcTJzwE3JC6AZEzYriVGzQpDMcgnSlZBJB8rKQhQZG6HbPnfVzZausK5pg6n1KlRLEzbam0r_VZrqU8_9WjMuclDbgKtdQPBfnYutXlbRuro2jfNd1AkXpUwAZclKeqsNPsbgyv0ZAnoLV_dwdYKrt3C1TDsXv__bb_zQTAbaG2KSmrkLeuG7kJDGf1K_AZjFhBI</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Shapiro, Ralph S.</creator><creator>Boyle, Marcia</creator><creator>Perez, Elena E.</creator><general>Springer US</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120901</creationdate><title>Local and National Advocacy Support</title><author>Shapiro, Ralph S. ; Boyle, Marcia ; Perez, Elena E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-6c704e777c33eb3ea61e68e04af4d02835c8f1a7bd518c4606ef086e07c6d5d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Decision Making, Organizational</topic><topic>Health Services Accessibility</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - economics</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Deficiency Syndromes - drug therapy</topic><topic>Immunologic Deficiency Syndromes - economics</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medical Microbiology</topic><topic>Patient Advocacy - economics</topic><topic>Patient Advocacy - legislation & jurisprudence</topic><topic>Patient Preference - economics</topic><topic>Patient Preference - legislation & jurisprudence</topic><topic>Precision Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shapiro, Ralph S.</creatorcontrib><creatorcontrib>Boyle, Marcia</creatorcontrib><creatorcontrib>Perez, Elena E.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shapiro, Ralph S.</au><au>Boyle, Marcia</au><au>Perez, Elena E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local and National Advocacy Support</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><addtitle>J Clin Immunol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>32</volume><issue>Suppl 2</issue><spage>423</spage><epage>426</epage><pages>423-426</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><abstract>Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient’s experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>22810627</pmid><doi>10.1007/s10875-012-9736-6</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-9142 |
| ispartof | Journal of clinical immunology, 2012-09, Vol.32 (Suppl 2), p.423-426 |
| issn | 0271-9142 1573-2592 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3459078 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Biomedical and Life Sciences Biomedicine Decision Making, Organizational Health Services Accessibility Humans Immunoglobulins, Intravenous - economics Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - drug therapy Immunologic Deficiency Syndromes - economics Immunology Infectious Diseases Internal Medicine Medical Microbiology Patient Advocacy - economics Patient Advocacy - legislation & jurisprudence Patient Preference - economics Patient Preference - legislation & jurisprudence Precision Medicine |
| title | Local and National Advocacy Support |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A15%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20and%20National%20Advocacy%20Support&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Shapiro,%20Ralph%20S.&rft.date=2012-09-01&rft.volume=32&rft.issue=Suppl%202&rft.spage=423&rft.epage=426&rft.pages=423-426&rft.issn=0271-9142&rft.eissn=1573-2592&rft_id=info:doi/10.1007/s10875-012-9736-6&rft_dat=%3Cproquest_pubme%3E1082235023%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1082235023&rft_id=info:pmid/22810627&rfr_iscdi=true |